Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors

aka IPMN, Pancreatic cyst, Mucinous cystic neoplasm, MCN, Pancreatic cystic neoplasm, Precancerous pancreatic cyst

Intraductal papillary mucinous neoplasms are fluid-filled growths in the pancreatic ducts that make mucus and can slowly turn into pancreatic cancer, one of the few chances to catch pancreatic cancer before it starts. Most are watched with scans for years, and surgery is reserved for the ones with warning signs such as a widened main duct, a solid nodule inside the cyst or jaundice.

Part ofPancreatic ductal adenocarcinoma

Intraductal papillary mucinous neoplasm (IPMN) is a mucin-producing epithelial neoplasm growing within the main pancreatic duct, its side branches or both. Main-duct and mixed-type IPMNs carry a substantial risk of high-grade dysplasia or invasive cancer at resection; branch-duct IPMNs, the commonest incidental cyst, progress in only a small minority over years. Mucinous cystic neoplasms (MCNs) occur almost only in women, in the body or tail, and have ovarian-type stroma; serous cystadenomas are benign and linked to VHL; solid pseudopapillary neoplasms are low-grade tumours of young women driven by CTNNB1. IPMNs carry KRAS and GNAS mutations early and acquire TP53, CDKN2A and SMAD4 changes as they progress, and cyst fluid analysis for CEA, glucose and mutations helps tell mucinous from non-mucinous cysts.

Management follows the international Fukuoka and Kyoto (2024) guidelines and the European consensus. High-risk stigmata (obstructive jaundice from a head cyst, an enhancing mural nodule of 5 mm or more, main duct of 10 mm or more, or positive cytology) call for resection in fit patients. Worrisome features (cyst of 3 cm or more, thickened enhancing wall, main duct 5 to 9 mm, smaller nodules, rapid growth, raised CA 19-9, new diabetes, pancreatitis) lead to endoscopic ultrasound with fluid sampling and closer surveillance. Cysts without these features are followed with MRI or endoscopic ultrasound at intervals set by size, and the question of when surveillance can stop in older patients with stable small cysts is unresolved.

Surgery is pancreatoduodenectomy or distal pancreatectomy; invasive cancer arising in an IPMN is staged and treated as pancreatic ductal adenocarcinoma, though colloid-type invasive IPMN carcinomas have a better outcome, and the remaining pancreas needs continued surveillance because IPMN is a field disease. Research aims at cyst fluid and blood biomarkers that separate the cysts that will progress from the many that never will, at artificial intelligence reading of scans, and at the link between new-onset diabetes and early pancreatic cancer.

State of the art

Risk-stratified surveillance under the Fukuoka and Kyoto guidelines avoids surgery for the large majority of cysts.
Cyst fluid mutation analysis separates mucinous from non-mucinous cysts and is entering routine use.
Artificial intelligence reading of CT and MRI and blood-based markers aim to predict which cysts progress.
The link between new-onset diabetes and early pancreatic cancer is being turned into a detection pathway.

Red cards

From the labels and guidelines behind the standard of care. Your team's thresholds win.

Emergency services now
Bleeding or bruising
Bleeding that will not stop, black or bloody stools, or unexplained bruising when platelets are expected to be low.
FOLFIRINOX / mFOLFIRINOX source

See all on the product pages:FOLFIRINOX / mFOLFIRINOX·Printable cards in the navigator

Anatomy and lymph node drainage

Pancreas and bile ducts: subsites and node stations · wireframe schematic, not to scale

Organ atlas →

Most pancreatic cancers arise in the head next to the bile duct, which is why jaundice is the presenting sign; bile duct cancers are named by where along the tree they sit.

Subsites

Pancreatic head (most PDAC)Main-duct IPMN (high risk of high-grade dysplasia or invasive PDAC; resection in fit patients) · Invasive carcinoma arising in an IPMN (tubular or colloid type; treated as ductal PDAC)
Body and tail
Ampulla
Islets (pancreatic NET)Main-duct IPMN (high risk of high-grade dysplasia or invasive PDAC; resection in fit patients)
Intrahepatic ducts
Perihilar (Klatskin)
Distal bile duct
Gallbladder

Regional lymph nodes

peripancreatic
hepatic hilar
coeliac and superior mesenteric

Who gets it and what has changed

Pancreatic cysts are found incidentally on scans in a few percent of adults and in a much larger share of people over 70; most are harmless, but intraductal papillary mucinous neoplasms and mucinous cystic neoplasms can progress to pancreatic cancer, and IPMNs are the precursor of a minority of pancreatic cancers.

Group

gastrointestinal

What is being done about this

Finding cancer earlier

and how the field plans to fix it →

Available now

High-risk pancreatic surveillance (CAPS / PRECEDE)Established
Liquid biopsy (ctDNA)Standard of care
MRIStandard of care

In trials

GalleriPhase 3
Multi-cancer early detection (MCED)Phase 3

Ideas and roadmaps

Background: CA 19-9. Also on OnCo: Symptoms and red flags · Early detection roadmap.

Cases by country

Cases by country · GLOBOCAN 2022

All countries →

No country-level case numbers. This cancer is not mapped to a GLOBOCAN site.

Standard of care

5top

Lines of therapy by subgroup →Staging and risk scores →

Decisions you may face

3 with more than one option · full decision page →

One section per setting: the options named, what each is for, the trials behind them, the recorded trade-offs and the questions to ask.

Incidental cyst3 High-risk stigmata Worrisome features2 Surveillance3 Invasive carcinoma in an IPMN

Incidental cyst

Characterise with MRI and MRCP or pancreas-protocol CT; endoscopic ultrasound with fluid analysis when the cyst type is unclear or worrisome features are present.

Kyoto guidelines for the management of IPMN (Pancreatology 2024)

MRI CT (computed tomography)Endoscopic ultrasound and EBUS systems CA 19-9

High-risk stigmata

Resection (pancreatoduodenectomy or distal pancreatectomy) for obstructive jaundice, an enhancing mural nodule of 5 mm or more, a main duct of 10 mm or more, or positive cytology, in patients fit for surgery.

Kyoto guidelines for the management of IPMN (Pancreatology 2024)

Whipple procedure (pancreaticoduodenectomy)Obstructive jaundice and biliary obstruction Robotic & minimally invasive surgery

Worrisome features

Endoscopic ultrasound and fluid sampling; resection or short-interval surveillance depending on findings, age and fitness.

Kyoto guidelines for the management of IPMN (Pancreatology 2024)

Endoscopic ultrasound and EBUS systems CA 19-9 MRI

Surveillance

MRI or endoscopic ultrasound at intervals set by cyst size, continued while the patient remains a surgical candidate; the remaining pancreas is followed after resection.

Kyoto guidelines for the management of IPMN (Pancreatology 2024)

MRI High-risk pancreatic surveillance (CAPS / PRECEDE)Endoscopic ultrasound and EBUS systems

Invasive carcinoma in an IPMN

Staged and treated as pancreatic ductal adenocarcinoma with resection and adjuvant chemotherapy.

NCCN Guidelines: Pancreatic Adenocarcinoma

Whipple procedure (pancreaticoduodenectomy)FOLFIRINOX / mFOLFIRINOXPRODIGE 24 / CCTG PA6

Subtypes & biomarkers

top

Subtypes

Main-duct IPMN (high risk of high-grade dysplasia or invasive PDAC; resection in fit patients)
Branch-duct IPMN without worrisome features (surveillance)
Branch-duct IPMN with worrisome features or high-risk stigmata (endoscopic ultrasound, resection)
Invasive carcinoma arising in an IPMN (tubular or colloid type; treated as ductal PDAC)
Mucinous cystic neoplasm (women, body or tail, ovarian-type stroma; resection)
Serous cystadenoma (benign; VHL association) and solid pseudopapillary neoplasm (CTNNB1; resection)

Biomarkers clinicians test

MRI with MRCP or pancreas-protocol CT : cyst size, main duct diameter, mural nodules, growth rate
Endoscopic ultrasound with cyst fluid CEA, glucose, cytology and KRAS, GNAS and other mutations
Serum CA 19-9 (worrisome feature when raised)
New-onset diabetes or pancreatitis (worrisome features)
Histological subtype of resected IPMN (gastric, intestinal, pancreatobiliary) and grade of dysplasia
TP53, SMAD4 and CDKN2A alterations in cyst fluid (investigational markers of progression)

How often this target appears

History

6top

1982Ohhashi describes mucin-producing pancreatic tumours, later named IPMN
Endoscopy (EGD, EUS, ERCP)
2006Sendai consensus guidelines for the management of IPMN and MCN
Resectable, borderline resectable and unresectable
2011GNAS mutations found in IPMNs, distinguishing them from other cysts
Comprehensive genomic profiling
2012Fukuoka guidelines introduce high-risk stigmata and worrisome features
MRI Endoscopic ultrasound and EBUS systems
2018European evidence-based guidelines on pancreatic cystic neoplasms
High-risk pancreatic surveillance (CAPS / PRECEDE)
2024Kyoto guidelines revise surveillance intervals and add cyst fluid molecular markers
Endoscopic ultrasound and EBUS systems CA 19-9

What changed

12top

Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.

All 12 changes by month →

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

In development

8top

What is in development for Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors, drawn from the whole corpus: 7 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.

Drugs in phase 3 · 1

Phase 3Multi-cancer early detection blood test

Galleri

Technologies being tested · 1

Multi-cancer early detection (MCED)

Ideas not yet in a trial · 5

Stop watching stable low-risk pancreatic cysts after five years Blood-based pancreatic cancer detection in new-onset diabetes New diabetes after 50 plus weight loss triggers a pancreatic cancer check AI that spots pancreatic cancer on scans taken a year before diagnosis Glucose monitor data as an early pancreatic cancer signal

Open problems and what is being done

Most cysts never progress, and no test yet identifies the minority that will.
Surveillance of a common incidental finding is costly and causes anxiety, and when it can safely stop is unknown.
Surgery for cysts carries real morbidity, and a share of resected cysts turn out to be low grade.
What is being done about this
Side effects and quality of life
and how the field plans to fix it →
Available now
Robotic & minimally invasive surgeryStandard of care
In trials
Nothing recorded yet.
Ideas and roadmaps
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
IPMN is a field disease, so cancer can arise elsewhere in the gland after resection.

Trials

top

Trials recruiting now

Recruiting trials near you · live from ClinicalTrials.gov

Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors

condition: Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors

Open on ClinicalTrials.gov →

within

Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.

Landmark trials

PRODIGE 24 / CCTG PA6

Expert centres

top

Where the expertise is

Expert centres

79 centres in 32 countries · 1 with a trial for this cancer on record · second-opinion finder →

Choose a region from the globe in the header to mark centres near you.

79 centres


Memorial Sloan Kettering Cancer Center New York · cancer center	United States	NCI comprehensive	0	5,100	94,456	Comprehensive genomic profiling CAR-T cell therapy Digital pathology & AI	#1
Mayo Clinic Rochester, MN · hospital	United States	NCI comprehensive	0	4,511	44,748	Carbon-ion therapy Proton therapy Proton therapy machines: cyclotrons, synchrotrons and single-room systems Gamma Knife +1	#5
Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center Baltimore · cancer center	United States	NCI comprehensive	0	2,955	41,449	Multi-cancer early detection (MCED)Liquid biopsy (ctDNA)Proton therapy Proton therapy machines: cyclotrons, synchrotrons and single-room systems +2	#10
Severance Hospital, Yonsei University Seoul · hospital	South Korea	none recorded	0	464	3,248	Carbon-ion therapy Robotic & minimally invasive surgery Carbon-ion synchrotrons and facilities Gamma Knife +1	#22
UNICANCER Paris · consortium	France	none recorded	1	not matched	-	HIPEC / PIPAC (intraperitoneal chemotherapy)	-
Zhongshan Hospital, Fudan University Shanghai · hospital	China	none recorded	0	2,872	31,534	Liquid biopsy (ctDNA)Thermal ablation (RFA, microwave, cryo)Robotic & minimally invasive surgery	-
Chris O'Brien Lifehouse Sydney · cancer center	Australia	none recorded	0	2,222	33,278	Robotic & minimally invasive surgery MR-guided adaptive radiotherapy Radioligand therapy (beta emitters)	-
Peking Union Medical College Hospital Beijing · hospital	China	none recorded	0	1,784	18,230	Robotic & minimally invasive surgery Germline (hereditary) testing	-
First Affiliated Hospital of Sun Yat-sen University Guangzhou · hospital	China	none recorded	0	1,245	12,931	Robotic & minimally invasive surgery HIPEC / PIPAC (intraperitoneal chemotherapy)	-
Tianjin Medical University Cancer Institute and Hospital Tianjin · cancer center	China	none recorded	0	1,219	11,455	IMRT / IGRT (modern external beam)Robotic & minimally invasive surgery Mammography & tomosynthesis	-
Chinese PLA General Hospital Beijing · hospital	China	none recorded	0	1,154	11,808	CAR-T cell therapy CRISPR functional genomics Robotic & minimally invasive surgery PET/CT	-
Centre Léon Bérard Lyon · cancer center	France	none recorded	0	1,071	14,301	Comprehensive genomic profiling Small-molecule kinase inhibitors Immune checkpoint inhibitors	-
Oslo University Hospital, The Norwegian Radium Hospital Oslo · cancer center	Norway	none recorded	0	936	11,600	Targeted alpha therapy Radioligand therapy (beta emitters)TCR-T cell therapy Proton therapy +1	-
Erasmus MC Cancer Institute Rotterdam · cancer center	Netherlands	none recorded	0	852	12,180	Radioligand therapy (beta emitters)SPECT & bone scan PET/CT Proton therapy +1	-
Institut Paoli-Calmettes Marseille · cancer center	France	none recorded	0	738	7,479	Allogeneic (off-the-shelf) cell therapy CAR-T cell therapy Comprehensive genomic profiling	-

(showing the first 15)

These are the things we can measure; they are not a ranking of quality. Each column is a field on the institution record or a count over what OnCo has linked; a centre that treats many patients with Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors but is thinly recorded here will look small.

Not known: OnCo holds no case-volume or outcome figures for centres, so none are shown. Where a national audit or registry publishes them, the centre's page links to it. Default order: Newsweek rank, then trials for this cancer, then research output.

Seeking a second opinion: ask your oncologist for a referral to a high-volume centre; most accept records and pathology by mail or telehealth. In the US, use the NCI's Find a Cancer Center tool or the nonprofit Cancer Commons, which navigates options for advanced cancers at no cost. The second-opinion finder explains how referral works in your country.

Questions to ask

top

Bring to your appointment

Questions to ask your oncologist about Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors

Generated from this cancer's standard of care, biomarkers, and pipeline · 16 questions

Newly diagnosed

What is my exact diagnosis, stage, and grade, and which tests established them?
Why: Everything else follows from an accurate stage and subtype.
Which biomarkers have been tested on my tumour (for example MRI with MRCP or pancreas-protocol CT: cyst size, main duct diameter, mural nodules, growth rate, Endoscopic ultrasound with cyst fluid CEA, glucose, cytology and KRAS, GNAS and other mutations, Serum CA 19-9, New-onset diabetes or pancreatitis, Histological subtype of resected IPMNand grade of dysplasia), and what were the results?
Why: These results decide eligibility for targeted therapy, immunotherapy, and trials.
Which subtype is my cancer, and does that change the recommended treatment?
Why: Recognised subtypes for this cancer include Main-duct IPMN, Branch-duct IPMN without worrisome features, Branch-duct IPMN with worrisome features or high-risk stigmata.
Is germline (inherited) genetic testing recommended for me or my family?
Why: Inherited variants can change treatment and matter for relatives.

Incidental cyst

For my situation (incidental cyst), which of the standard options do you recommend and why?
Why: Guideline options include: Characterise with MRI and MRCP or pancreas-protocol CT; endoscopic ultrasound with fluid analysis when the cyst type is unclear or worrisome features are present.

High-risk stigmata

For my situation (high-risk stigmata), which of the standard options do you recommend and why?
Why: Guideline options include: Resection (pancreatoduodenectomy or distal pancreatectomy) for obstructive jaundice, an enhancing mural nodule of 5 mm or more, a main duct of 10 mm or more, or positive cytology, in patients fit for surgery.

Worrisome features

For my situation (worrisome features), which of the standard options do you recommend and why?
Why: Guideline options include: Endoscopic ultrasound and fluid sampling; resection or short-interval surveillance depending on findings, age and fitness.

Surveillance

For my situation (surveillance), which of the standard options do you recommend and why?
Why: Guideline options include: MRI or endoscopic ultrasound at intervals set by cyst size, continued while the patient remains a surgical candidate; the remaining pancreas is followed after resection.

Invasive carcinoma in an IPMN

For my situation (invasive carcinoma in an ipmn), which of the standard options do you recommend and why?
Why: Guideline options include: Staged and treated as pancreatic ductal adenocarcinoma with resection and adjuvant chemotherapy.
Am I a candidate for FOLFIRINOX / mFOLFIRINOX, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
How do the results of PRODIGE 24 / CCTG PA6 apply to someone like me?
Why: Trial populations differ from individual patients; ask how closely you match.

Any stage

Are there clinical trials I could join, for example of Stop watching stable low-risk pancreatic cysts after five years, Blood-based pancreatic cancer detection in new-onset diabetes, New diabetes after 50 plus weight loss triggers a pancreatic cancer check, AI that spots pancreatic cancer on scans taken a year before diagnosis?
Why: Trials are how the next standard of care is set; asking early keeps options open.
Would a second opinion at a high-volume centre change anything, and can you help arrange it?
Why: Rare or high-stakes decisions benefit from a centre that treats many similar patients.
What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
Why: Supportive care improves quality of life and helps patients complete treatment.
I read that “Most cysts never progress, and no test yet identifies the minority that will”. How does that affect my plan?
Why: Open problems are where trials and second opinions matter most.
I read that “Surveillance of a common incidental finding is costly and causes anxiety, and when it can safely stop is unknown”. How does that affect my plan?
Why: Open problems are where trials and second opinions matter most.